Clinical trial · Interventional
Microbiota and the Lung Cancer
Characterization of Microbiota (Intestinal, From Lungs, and Upper Airways) in Patients With Non-small Cell Lung Carcinoma: Exploratory Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The subject is to study the lung microbiota and the one of upper airways (UAs) (much less studied than the intestinal microbiota) in 40 patients having lung cancer. 20 patients undergo only surgical treatment, while other half receives also chemotherapy. The idea is to explore changes in microbiota of the lung, upper UAs and intestine, and potentially find associations between them. These results will serve us as a base for the future study, focused on manipulation of the microbiota by prebiotics, probiotics or symbiotics and its effect on anti-cancer treatment tolerance and effectiveness.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Pchir
- description
- Non small cell lung carcinoma patients designated for immediate surgery. Intervention in this group is "sampling". The sampling will be done for: * blood and saliva: at consultations after inclusion in the study * faeces: day before the surgery * lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy
- interventionNames
- Other: Sampling
- type
- EXPERIMENTAL
- label
- Pct-chir
- description
- Non small cell lung carcinoma patients who will receive neoadjuvant chemotherapy before the surgery. Intervention in this group is "sampling". The sampling will be done for: * blood and saliva: 1st time at consultations after inclusion in the study, 2nd time at consultations after chemotherapy and before surgery * faeces: 1st time the day before the chemotherapy, 2nd time the day before the surgery * lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy
- interventionNames
- Other: Sampling
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * non small cell lung carcinoma patient suitable for surgery, or chemotherapy followed by surgery * BMI \<29.9 kg/m² * not taking antibiotics, corticosteroids and/or immunosuppressants at least during two months before inclusion * not taking prebiotics, probiotics or symbiotics at least during two months before inclusion * signing the written consent before enrollment in the study * affiliation to the national health insurance (or system alike) according to the law from 9th August 2004 Exclusion Criteria: * cognitive difficulties * refusal of participation or inability to give a clear consent * digestive or pulmonary infection of a long duration during the two months preceding the study (with antibiotic treatment) * inflammatory digestive pathology * concurrent treatment with experimental medication, participation in another clinical therapeutic study within 30 days * presence of colostomy, total or partial gastrectomy * previous esophageal surgery * previous ORL (otho-rhino-laryngo) cancer treated by radiotherapy or surgery * patient enable to follow the requirements of the study * patient deprived of his rights by administrative or judicial decision
References
Publications (2)
- BACKGROUNDMontassier E, Gastinne T, Vangay P, Al-Ghalith GA, Bruley des Varannes S, Massart S, Moreau P, Potel G, de La Cochetiere MF, Batard E, Knights D. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015 Sep;42(5):515-28. doi: 10.1111/apt.13302. Epub 2015 Jul 6. PMID 26147207
- DERIVEDBingula R, Filaire E, Molnar I, Delmas E, Berthon JY, Vasson MP, Bernalier-Donadille A, Filaire M. Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial. Respir Res. 2020 May 25;21(1):129. doi: 10.1186/s12931-020-01392-2. PMID 32450847